Samsun University Faculty of Medicine Samsun Training and Research Hospital
Samsun, Turkey (Türkiye)
Location status: Recruiting
NCT Number: NCT07745036
Preeclampsia is a pregnancy-specific hypertensive disorder and remains a leading cause of maternal and perinatal morbidity and mortality worldwide. Although abnormal placentation, impaired trophoblast invasion, endothelial dysfunction, and immune dysregulation have been implicated in its pathogenesis, the underlying molecular mechanisms are not fully understood.
Progesterone plays a critical role in the maintenance of pregnancy through both classical nuclear receptors and membrane-associated progesterone receptors. Emerging evidence suggests that progesterone membrane receptors, including progesterone receptor membrane component 1 (PGRMC1), progesterone receptor membrane component 2 (PGRMC2), and members of the progestin and adipoQ receptor (PAQR) family, may regulate trophoblast invasion, placental development, and inflammatory responses.
This study aims to compare the placental expression levels of PGRMC1, PGRMC2, and PAQR family receptors between women with preeclampsia and healthy pregnant controls and to investigate their potential role in the pathophysiology of preeclampsia.
Interested in participating?
Request Info18 year–45 year
Female
Observational
Samsun, Turkey (Türkiye)
Location status: Recruiting
Preeclampsia affects approximately 3-8% of pregnancies and is characterized by new-onset hypertension and multisystem involvement after 20 weeks of gestation. Despite extensive research, its molecular pathogenesis remains incompletely understood.
Progesterone is essential for successful pregnancy maintenance and contributes to uterine quiescence, trophoblast function, and maternal-fetal immune tolerance. In addition to classical genomic signaling pathways, progesterone exerts rapid non-genomic effects through membrane-associated receptors, including PGRMC1, PGRMC2, and PAQR family members.
Recent studies have demonstrated that these receptors are involved in trophoblast invasion, angiogenesis, endothelial function, and inflammatory regulation. Alterations in their expression may contribute to abnormal placentation and endothelial dysfunction observed in preeclampsia.
The present study will evaluate placental expression levels of PGRMC1, PGRMC2, and selected PAQR family receptors in women with preeclampsia and healthy controls. Placental tissue obtained after delivery will undergo immunohistochemical and mRNA expression analyses. The findings may improve understanding of the molecular mechanisms underlying preeclampsia and identify potential biomarkers or therapeutic targets.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Preeclampsia Group Women aged 18-45 years Singleton pregnancy Diagnosis of preeclampsia according to ACOG criteria Delivery at the study center Written informed consent Control Group Women aged 18-45 years Singleton pregnancy Normotensive healthy pregnancy Delivery at the study center Written informed consent
Exclusion criteria
Age <18 or >45 years Multiple gestation Fetal structural or chromosomal anomalies Chronic hypertension Pre-existing diabetes mellitus Autoimmune diseases Renal disease Other major systemic disorders
-
Time frame: At delivery
Quantitative comparison of placental receptor expression levels between preeclamptic and healthy pregnancies using immunohistochemical and mRNA-based analyses.
Contact information is provided by the study sponsor or research team.
Canan Soyer Çalışkan, MD, Associate Professor
CONTACT
Canan Soyer Çalışkan, MD, Associate Professor
CONTACT
90 362 311 15 40 ext. 90 532 203 55
Samsun University
Other
Investigation of Progesterone Membrane Receptor Expression in Placental Tissue of Women With Preeclampsia and Their Potential Role in the Pathogenesis of Preeclampsia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07448597
Female Urogenital Diseases and Pregnancy Complications, Hypertension, Pregnancy-Induced
Charleston, South Carolina, United States
View Trial DetailsNCT07199283
Body Weight, Cardiovascular Diseases
Stockholm, Stockholm County, Sweden
View Trial DetailsNCT06033131
Birth Weight, Body Weight
Helsinki, Finland
View Trial DetailsNCT07222852
Cardiovascular Diseases, Female Urogenital Diseases and Pregnancy Complications
Providence, Rhode Island, United States
View Trial Details